ProCE Banner Activity

ALLIANCE: Phase III Randomized Controlled Trial of BIC/FTC/TAF vs DTG + FTC/TDF in Treatment-Naive Adults With HIV/HBV Coinfection

Slideset Download
Conference Coverage
Significantly greater proportion of patients with HIV/HBV coinfection achieved HBV DNA <29 IU/mL with BIC/FTC/TAF vs DTG + FTC/TDF at 48 weeks; HIV outcomes were similar with both regimens.

Released: August 03, 2022

Expiration: August 02, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare


IAS 2021

ProCE Banner